首页> 外文期刊>Journal of drugs in dermatology: JDD >Efficacy and safety of topical calcitriol 3 microg/g ointment, a new topical therapy for chronic plaque psoriasis.
【24h】

Efficacy and safety of topical calcitriol 3 microg/g ointment, a new topical therapy for chronic plaque psoriasis.

机译:局部骨化三醇3微克/克软膏的功效和安全性,一种新型的慢性斑块状牛皮癣局部疗法。

获取原文
获取原文并翻译 | 示例
           

摘要

Topical vitamin D modulators are among the most widely used medications for the treatment of psoriasis. Calcitriol, the naturally occurring active form of vitamin D3, has long been used for topical psoriasis therapy in Europe and other parts of the world and was recently approved in the United States. Calcitriol 3 microg/g ointment has been extensively evaluated for the treatment of chronic plaque-type psoriasis and has been shown to be effective, safe and well-tolerated in a number of short-term and long-term clinical trials. Pharmacokinetic studies in patients with psoriasis and healthy control subjects have demonstrated that topical calcitriol ointment produces little systemic absorption of calcitriol and does not alter systemic calcium homeostasis significantly even when applied to approximately one third of the body surface area. Calcitriol ointment is associated with a low rate of cutaneous irritation and does not increase the sensitivity of treated skin to phototoxicity following treatment with ultraviolet treatment. In two randomized, double-blind clinical trials, twice-daily application of calcitriol ointment for eight weeks resulted in clearing or minimal residual psoriasis in approximately 34% of patients, compared with 12% to 22.5% of patients treated with vehicle ointment (P=0.005 in study 1 and P<0.001 in study 2). Calcitriol ointment also significantly improved ratings of individual psoriasis signs and symptoms of plaque elevation, erythema, scaling and pruritus compared to vehicle. In two long-term studies in which patients were treated with calcitriol ointment for a year or longer, calcitriol ointment produced sustained improvement in physician-rated and patient-rated psoriasis severity. Calcitriol ointment was associated with a low risk of adverse events after one year and did not alter laboratory measures of calcium or phosphorus metabolism in a clinically significant manner. The results of these studies suggest that calcitriol 3 microg/g ointment is an effective, safe and well-tolerated topical psoriasis therapy. Calcitriol ointment offers considerable flexibility for use in a variety of monotherapy and combination therapy regimens for patients with psoriasis.
机译:局部维生素D调节剂是治疗牛皮癣最广泛使用的药物之一。骨化三醇是维生素D3的天然活性形式,长期以来一直在欧洲和世界其他地区用于局部牛皮癣治疗,最近在美国获得批准。骨化三醇3微克/克软膏已被广泛评估用于治疗慢性斑块型牛皮癣,并已在许多短期和长期临床试验中证明有效,安全且耐受性良好。在银屑病患者和健康对照对象中进行的药代动力学研究表明,局部骨化三醇软膏几乎不会产生骨化三醇的全身吸收,即使将其应用于约三分之一的身体表面积,也不会显着改变全身性钙稳态。骨化三醇软膏与皮肤刺激率低相关,并且在紫外线处理后不会增加被处理皮肤对光毒性的敏感性。在两项随机,双盲的临床试验中,每天两次应用骨化三醇软膏治疗八周可导致约34%的患者清除或残留银屑病最少,相比之下,接受载体软膏治疗的患者为12%至22.5%(P =研究1为0.005,研究2为P <0.001)。与媒介物相比,骨化三醇软膏还显着改善了个体牛皮癣体征和斑块升高,红斑,脱屑和瘙痒症状的等级。在两项用骨化三醇软膏治疗患者一年或更长时间的长期研究中,骨化三醇软膏在医师评估和患者评估的牛皮癣严重程度方面持续改善。骨化三醇软膏与一年后不良事件的低风险相关,并且不会以临床上显着的方式改变钙或磷代谢的实验室指标。这些研究结果表明,骨化三醇3微克/克软膏是一种有效,安全且耐受良好的局部牛皮癣治疗方法。骨化三醇软膏为牛皮癣患者的各种单一疗法和联合疗法提供了极大的灵活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号